Literature DB >> 30660740

N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion.

Daniela Impellizzeri1, Rosalba Siracusa1, Marika Cordaro1, Rosalia Crupi1, Alessio Filippo Peritore1, Enrico Gugliandolo1, Ramona D'Amico1, Stefania Petrosino2, Maurizio Evangelista3, Rosanna Di Paola1, Salvatore Cuzzocrea4.   

Abstract

AIM: Recent studies revealed that pharmacological modulation of NAE-hydrolyzing acid amidase (NAAA) can be achieved with PEA oxazoline (PEA-OXA). Hence, the aim of the present work was to thoroughly evaluate the anti-inflammatory and neuroprotective effects of PEA-OXA in an experimental model of vascular dementia (VaD) induced by bilateral carotid arteries occlusion. At 24 h after VaD induction, animals were orally administered with 10 mg/kg of PEA-OXA daily for 15 days.
RESULTS: Brain tissues were handled for histological, immunohistochemical, western blot, and immunofluorescence analysis. PEA-OXA treatment evidently reduced the histological alterations and neuronal death induced by VaD and additionally improved behavioral deficits. Further, PEA-OXA decreased GFAP and Iba-1, markers of astrocytes, and microglia activation, as well as increased MAP-2, a marker of neuron development. Moreover, PEA-OXA reduced oxidative stress, modulated Nrf2-mediated antioxidant response, and inhibited the apoptotic process. INNOVATION: Some drugs may demonstrate their healing potential by regulating neuroinflammation, rather than by their habitually attributed actions only. Palmitoylethanolamide (PEA) is a prototype ALIAmide, well-known for its analgesic, anti-inflammatory, and neuroprotective properties. The inhibition of PEA degradation by targeting NAAA, its catabolic enzyme, is a different approach for treating neuroinflammation. This research offers new insight into the mechanism of PEA-OXA-induced neuroprotection.
CONCLUSION: Thus, the modulation of intracellular NAAA by PEA-OXA could offer a novel means of controlling neuroinflammatory conditions associated with VaD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Neuroprotection; Oxazoline; Oxidative stress; Palmitoylethanolamide

Year:  2019        PMID: 30660740     DOI: 10.1016/j.nbd.2019.01.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  22 in total

1.  Evaluation of Neuroprotective Effects of Quercetin against Aflatoxin B1-Intoxicated Mice.

Authors:  Enrico Gugliandolo; Alessio Filippo Peritore; Ramona D'Amico; Patrizia Licata; Rosalia Crupi
Journal:  Animals (Basel)       Date:  2020-05-21       Impact factor: 2.752

2.  Role of Etanercept and Infliximab on Nociceptive Changes Induced by the Experimental Model of Fibromyalgia.

Authors:  Marika Cordaro; Rosalba Siracusa; Ramona D'Amico; Tiziana Genovese; Gianluca Franco; Ylenia Marino; Davide Di Paola; Salvatore Cuzzocrea; Daniela Impellizzeri; Rosanna Di Paola; Roberta Fusco
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

3.  Phosphatidylethanolamine Deficiency and Triglyceride Overload in Perilesional Cortex Contribute to Non-Goal-Directed Hyperactivity after Traumatic Brain Injury in Mice.

Authors:  Lisa Hahnefeld; Alexandra Vogel; Robert Gurke; Gerd Geisslinger; Michael K E Schäfer; Irmgard Tegeder
Journal:  Biomedicines       Date:  2022-04-15

Review 4.  Senescent Microglia: The Key to the Ageing Brain?

Authors:  Eleanor K Greenwood; David R Brown
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 5.  Early Life Oxidative Stress and Long-Lasting Cardiovascular Effects on Offspring Conceived by Assisted Reproductive Technologies: A Review.

Authors:  Huixia Yang; Christina Kuhn; Thomas Kolben; Zhi Ma; Peng Lin; Sven Mahner; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

Review 6.  Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease.

Authors:  Sarah Beggiato; Maria Cristina Tomasini; Luca Ferraro
Journal:  Front Pharmacol       Date:  2019-07-24       Impact factor: 5.810

Review 7.  Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets.

Authors:  Alessio Filippo Peritore; Rosalba Siracusa; Rosalia Crupi; Salvatore Cuzzocrea
Journal:  Nutrients       Date:  2019-09-11       Impact factor: 5.717

Review 8.  Targeting Transcription Factor Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2) for the Intervention of Vascular Cognitive Impairment and Dementia.

Authors:  Tuo Yang; Feng Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-15       Impact factor: 8.311

9.  Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach.

Authors:  Alessio Filippo Peritore; Ramona D'Amico; Rosalba Siracusa; Marika Cordaro; Roberta Fusco; Enrico Gugliandolo; Tiziana Genovese; Rosalia Crupi; Rosanna Di Paola; Salvatore Cuzzocrea; Daniela Impellizzeri
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

Review 10.  An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events.

Authors:  Marika Cordaro; Salvatore Cuzzocrea; Rosalia Crupi
Journal:  Antioxidants (Basel)       Date:  2020-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.